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Abstract 
Objective: To test the hypothesis that zoledronic acid will inhibit tumor-induced osteolysis and 
reduce tumor growth and invasion in a xenograft mouse model of bone invasive oral squamous 
cell carcinoma (OSCC). In humans, OSCC is the 6th most common cancer in the world. Bone 
invasion frequently occurs and is associated with poor prognosis and reduced survival. OSCC is 
the most commonly diagnosed malignancy of the oral cavity in cats and has a grave prognosis 
with an average duration of survival of only 2 months. Feline OSCC (FOSCC) is very aggressive 
and commonly invades bone, which is characterized by osteoclastic bone resorption. Zoledronic 
acid (ZOL) is a potent third generation nitrogen-containing bisphosphonate which inhibits 
osteoclastic bone resorption. There are currently no available treatment modalities which 
significantly improve prognosis or prolong survival of cats with FOSCC. Methods: A luciferase-
expressing FOSCC cell line (SCCF2Luc) was injected into the perimaxillary subgingival lamina 
propria of 30 athymic nude mice. Mice were treated with 100 µg/kg ZOL, or vehicle, twice 
weekly for 4 weeks. Thirty non-tumor-bearing mice served as controls. Tumor growth was 
monitored with in vivo bioluminescent imaging and tumor dimensions were determined with 
calipers. The degree of bone loss was evaluated using faxitron radiography and micro-computed 
tomography (microCT). A 2mm thick region of interest (ROI) in the rostral skull, incorporating 
the xenograft and adjacent pre-maxillary and maxillary bone, was selected using µCT and image 
analysis software. ROI-bone surface area and bone volume were calculated and compared 
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between treatment groups. Tumor invasiveness was evaluated microscopically. Osteolysis and 
osteoclast activation were evaluated with TRAP histochemistry and histomorphometry. Results 
and conclusions: Progressive xenograft growth occurred in all mice, as indicated by increasing 
bioluminescence. Bioluminescence was positively correlated with tumor volume. ZOL treatment 
significantly reduced tumor growth (in vivo bioluminescence), prevented loss of bone volume 
and surface area (microCT), and was associated with reduced osteolysis and increased periosteal 
new bone formation (microCT, faxitron radiography and histomorphometry). ZOL had no effect 
on tumor invasion around the incisor or into the nasal cavity. ZOL-mediated inhibition of tumor-
induced osteolysis was characterized by significantly reduced numbers of TRAP-positive 
osteoclasts at the tumor-bone interface and was associated with osteoclast vacuolar degeneration. 
The ratio of eroded to total bone surface was not significantly affected by treatment; indicating 
that ZOL-mediated inhibition of osteolysis was independent of osteoclast activation and 
maturation.  
Significance:  This preclinical model of OSCC recapitulates the bone invasive phenotype 
characteristic of the disease in both humans and cats, and will be useful to future preclinical 
studies of bone invasive OSCC regardless of species. ZOL reduced FOSCC-induced osteolysis 
and bioluminescence, but invasive behavior was unchanged. The results of this experiment 
suggest that ZOL monotherapy would be of limited clinical use in the management of FOSCC, 
but may be valuable as adjunct therapy with the purpose of maintaining mandibular and 
maxillary bone volume and function.  
Introduction 
Squamous cell carcinoma is the most common form of oral cancer in both humans (1-3) and 
domestic cats (4-5). Destruction and invasion of mandibular and maxillary bone frequently 
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occurs and contributes to morbidity and mortalilty (6, 7). Feline oral squamous cell carcinoma 
(FOSCC) is the most commonly diagnosed tumor of the oral cavity in cats. It is an extremely 
aggressive cancer characterized by profound destruction of oral tissues and frequently invades 
bone (8). Surgical removal may be curative in early cases but is associated with significant 
morbidity (9, 10), or their tumors are so extensive that they are no longer surgical candidates (8). 
FOSCC-associated bone destruction contributes significantly to patient morbidity and mortality.     
   The mechanism of FOSCC-induced osteoclastic bone resorption is unknown. We hypothesize 
that FOSCC invasion into bone is facilitated by a vicious cycle of tumor growth and bone 
resorption which can be abrogated by targeting bone-resorbing osteoclasts. The vicious cycle 
theory was originally described in human breast cancer bone metastasis as a relationship between 
the tumor-derived PTHrP (agonist of osteoclastic bone resorption) and bone derived TGF-β 
(stimulates tumor-expression of PTHrP with increased tumor growth and invasion) (11), 
however other OSCC-derived cytokines may contribute to osteolysis, including prostaglandin E2 
(PGE2) (12, 13), parathyroid hormone related-protein (PTHrP), tumor necrosis factor-alpha 
(TNF-α), interleukin-6 and interleukin-11 (14-16).   
   Regardless of the number and type of bone resorption agonists expressed by FOSCC cells, 
tumor-associated osteoclastic bone resorption can be inhibited by nitrogen-containing 
bisphosphonates (NBPs). NBPs such as zoledronic acid (ZOL) inhibit osteoclasts by inhibiting 
farnesyl pyrophosphate synthase in the mevalonate (MVA) pathway (17, 18). Inhibition of the 
MVA pathway leads to reduced prenylation of small guanosine-triphosphate (GTP)-binding 
proteins (Rab, Rac and Rho) responsible for osteoclast function and results in osteoclast 
apoptosis (19, 20). We hypothesize that inhibition of osteoclastic bone resorption with ZOL will 
not only reduce bone loss but will also inhibit OSCC xenograft growth and invasion by 
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antagonizing the vicious cycle of osteolysis and tumor progression. 
      We have designed a novel bone-invasive, bioluminescent orthotopic xenograft nude mouse 
model of FOSCC using cells derived from a bone invasive FOSCC. The inhibitory activity of 
ZOL on FOSCC growth and associated osteolysis was investigated using bioluminescent 
imaging, radiographs, micro-computed tomography and maxillary histomorphometry. We found 
that ZOL may be an effective treatment for preventing bone resorption in FOSCC. 
Materials and Methods 
Cells and reagents. SCCF2 cells were derived from a bone-invasive gingival squamous cell 
carcinoma of a 7-year old male castrated domestic shorthaired cat using methods previously 
described (21). Zoledronic acid (Zometa; Novartis) was purchased from the James Cancer Center 
at The Ohio State University. ZOL vehicle was prepared according to the package insert and 
consisted of 44 mg/ml mannitol and 4.8 mg/ml sodium acetate in sterile water.  
Transfection of SCCF2 cells with luciferase gene. SCCF2 cells were stably transfected with a 
plasmid containing a luciferase-yellow fluorescent protein (YFP) fusion construct 
(pCDNA3.1(+).yLuc-YFP) using Lipofectamine™ LTX and PLUS™ Reagent (Invitrogen) 
according to the manufacturer’s instructions. Luciferase expression of individual colonies was 
determined using the Xenogen IVIS 200 system in growth medium supplemented with 142.5 
μg/ml D-Luciferin (Xenogen, Alameda, CA). Three colonies with the highest bioluminescence 
were pooled to create the luciferase-expressing cell line SCCF2Luc.  
Animals and treatments. Animal procedures were approved by the Institutional Lab Animal Care 
and Use Committee. Sixty 6-week-old male nu/nu mice (NCI, Frederick, MD) were randomly 
assigned to 1 of 4 groups; non tumor-bearing vehicle-treated mice, tumor-bearing vehicle-treated 
mice, non tumor-bearing ZOL-treated mice and tumor-bearing ZOL-treated mice. Mice were 
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anesthetized with isofluorane and injected with 1x106 SCCF2Luc cells in 0.1ml PBS, 
subgingivally, adjacent to the maxilla. Non-tumor bearing mice were injected with cell-free PBS. 
Treatment was initiated 7 days following SCCF2Luc injection, and consisted of twice weekly 
subcutaneous injections of 100 μg/kg ZOL or vehicle. Bioluminescent images were collected 
1,7,21 and 28 days following the initiation of treatment. Mice were sacrificed on day 28 and 
blood was collected for determination of PTHrP and total calcium levels.  
Bioluminescent imaging. Bioluminescent imaging was done with the in vivo imaging system 
(IVIS, Caliper Life Sciences) as previously described (22). Photon signals were quantified with 
LivingImage software version 2.2 (Caliper life sciences). 
Faxitron radiography and micro-computed tomography. The mandible was removed from each 
skull and the degree of maxillary and premaxillary bone loss was evaluated qualitatively using a 
Faxitron cabinet X-ray system (Hewlett-Packard, McMinnville, OR). Bone loss was evaluated 
quantitatively using micro-computed tomography (microCT, Inveon, Siemens AG, Munich, 
Germany). Image data was reconstructed using Cobra software (Exxim, Pleasanton CA) and 
analyzed using Inveon 3D analysis software. Intensity thresholds were determined for selecting 
bone from surrounding soft tissue and were kept constant for all mice. Bone surface area and 
bone volume were determined for a 2 mm thick ROI in the region of xenograft growth and 
compared between treatment groups.  
Histopathology, TRAP histochemistry and histomorphometry. Skulls were routinely fixed and 
decalcified. Enzymatic histochemistry for tartrate-resistant acid phosphatase (TRAP, Sigma-
Aldrich) was done as previously described (23). Bone histomorphometry was done with 
Imagescope software (Aperio). Percentage of eroded bone, percentage of bone in contact with 
activated osteoclasts, number of activated osteoclasts, and average osteoclast length were 
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determined for treated and untreated tumor-bearing mice. Only sections with a minimum of 3mm 
of direct tumor-bone interface were included. Tissues were also evaluated for the presence of 
tumor invasion around the maxillary incisor and into the nasal cavity.   
Plasma PTHrP and Calcium. Plasma PTHrP (1-86) was measured using a commercially 
available two-site immunoradiometric assay (Diagnostic Systems Laboratories Inc., Webster, 
TX, USA). Plasma calcium concentration was determined using a commercially available 
calcium assay kit (Bioassay Systems, Hayward, CA). Both assays were performed according to 
the manufacturer’s instructions. 
Statistical analysis. Results are displayed as means with standard deviation. Normally distributed 
data were analyzed using Student’s t-test or one-way ANOVA with Bonferroni’s post hoc test. 
Data not normally distributed was evaluated with Wilcoxon rank sum (Mann-Whitney) test. P 
values less than 0.05 were considered statistically significant. Categorical data was analyzed 
using Fishers exact test. All analysis were performed with STATA intercooled 10 (Cary, NC). 
Results 
ZOL treatment reduced tumor growth but not rate of invasion. Progressive xenograft growth was 
observed in all mice. Radiance values were normalized by dividing measurements on days 7, 21 
and 28 by radiance of day 1 and expressed as fold change radiance. At the 28th day, ZOL 
treatment reduced fold change radiance by 43% compared to the vehicle-treated mice (P=0.004, 
figure 1). Histomorphometry revealed that ZOL-treatment reduced adjusted tumor area (total 
area minus areas of necrosis) by 14% (P=0.0375, figure 2). Bioluminescent imaging was more 
sensitive than calculating tumor volume from caliper measurements (data not shown) or 
histomorphometric evaluation of tumor area. Tumor invasion around the maxillary incisor was 
observed in 13 of 15 vehicle treated mice, and invasion into the nasal cavity was observed in 12 
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of 15 mice. The incidence of invasion did not significantly differ in ZOL treated mice.    
Zoledronic acid reduces bone resorption. ZOL qualitatively reduced radiographic evidence of 
osteolysis and increased periosteal new bone formation in the region of xenograft growth (figure 
3). MicroCT revealed that xenograft growth in vehicle treated mice was associated with a 13.9% 
loss of bone surface area (P<0.0001) and an 18.9% reduction in bone volume (P<0.0001, figure 
4). ZOL-treatment prevented statistically significant loss of bone surface area and bone volume.  
   Histologic examination revealed that ZOL-treated mice retained more bone than vehicle-
treated mice (figure 5). Maxillary histomorphometry demonstrated that SCCF2Luc xenograft 
growth was associated with a 47.7% reduction in total bone area (preexisting bone and new bone 
combined) compared to the non-tumor bearing side (P=0.0002), whereas ZOL treatment 
prevented loss of total bone area (figure 6). Loss of preexisting bone was reduced from 64.1% in 
untreated mice to 33.3% in ZOL-treated mice (P=0.005, figure 6). The preservation of total bone 
in ZOL-treated mice, as detected by microcomputed tomography and histomorphometry, is 
attributed to reduced loss of preexisting bone and increased new bone formation.  
Zoledronic acid treatment resulted in fewer osteoclast numbers with vacuolar degeneration. 
Histomorphometric evaluation of TRAP-stained slides revealed no difference in the ratio of 
eroded to total bone surface between ZOL and vehicle treated mice, suggesting that xenograft-
mediated recruitment and maturation of osteoclasts and initiation of bone resorption was not 
affected by ZOL-treatment. ZOL reduced the percentage of bone surface in direct contact with 
osteoclasts by 33.4% (P=0.017, figure 7). ZOL reduced the number of osteoclasts per millimeter 
by 51.8% (P=0.0001). The average osteoclast length was increased in the ZOL-treated mice by 
39.1% (P=0.0001), which was characterized by cytoplasmic dilation with numerous, variably 
sized, circular, clear cytoplasmic vacuoles (vacuolar degeneration, figure 8).  
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ZOL failed to reduce plasma PTHrP in tumor bearing mice. Xenograft growth and ZOL-
treatment had no effect on plasma calcium compared to control mice. Plasma PTHrP was 
elevated in tumor bearing mice (2.42 pM) compared to control mice (0.65pM, P=0.037, figure 
9); however ZOL treatment did not significantly reduce plasma PTHrP values. 
Discussion 
   Prior to this study, there have been no preclinical models which recapitulate the bone invasive 
behavior of FOSCC in which to evaluate therapeutic agents. We have designed a novel, bone 
invasive, bioluminescent orthotopic xenograft nude mouse model of OSCC using feline cells 
derived from a bone invasive  FOSCC, and have demonstrated that ZOL treatment effectively 
reduced tumor growth and bone resorption associated with FOSCC xenograft growth.  
   SCCF2Luc xenografts induced osteoclastic bone resorption characterized by numerous 
activated osteoclasts at the tumor-bone interface. The mechanism by which FOSCC stimulates 
osteoclastic bone resorption is unknown, however we hypothesize that FOSCC invasion into 
bone is facilitated by a vicious cycle of tumor growth and bone resorption. Chirgwin and Guise 
(11) first proposed that osteolytic breast cancer metastasis in humans results from a relationship 
between tumor-derived PTHrP and bone derived TGF-β. Virtually all squamous cell carcinomas 
produce PTHrP (24, 25), including those of the feline oral cavity (21). We have used 
immunohistochemistry to demonstrate that spontaneous FOSCC tumors express PTHrP, and that 
the degree of PTHrP positivity increases in tumors associated with bone resorption (unpublished 
data). TGF-β causes increased secretion of PTHrP from tumor cells, and is known to increase 
FOSCC-expression of PTHrP in vitro (21). It is widely recognized that PGE2 stimulates 
osteoclastogenesis through the up-regulation of RANKL expression in osteoblasts and bone 
marrow stromal cells (26). In human OSCC, high levels of PGE2 are due to up-regulation of 
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COX-2 (27), which is also over-expressed in OSCC of cats (28, 29).  
   ZOL therapy may have reduced xenograft growth indirectly by inhibiting the vicious cycle 
through inhibition of osteoclastic bone resorption, or through direct antineoplastic mechanisms. 
Preclinical research suggests that bisphosphonates may exert antitumor effects by inhibiting 
cancer cell adhesion, invasion, viability and angiogenesis (30-32). The inhibitory effect of 
bisphosphonates on angiogenesis may be the result of reduced circulating levels of VEGF. ZOL 
acid therapy has been shown to reduce circulating VEGF in humans with metastatic bone disease 
(33), and in a preliminary clinical trial in cats with OSCC (34). Early clinical reports have 
demonstrated that human cancer patients benefit from reduced skeletal metastasis and improved 
prognosis when bisphosphonates are included in their treatment regimens (33). A third 
generation bisphosphonate (YM529) prevented bone invasion and inhibited tumor growth in a 
syngeneic mouse model of OSCC (16).   
   ZOL inhibits osteoclastic bone resorption by inducing osteoclastic apoptosis through impaired 
prenylation of small GTPases as a result of farnesyl transferase inhibition (17, 18). Our study 
revealed that osteoclasts in ZOL treated mice continued to form and maintained their ability to 
resorb bone, but existed in reduced numbers and demonstrated evidence of vacuolar 
degeneration. The mechanism of this vacuolar degeneration is not known, however a study by 
Coxon et al. (2003) demonstrated that targeted inhibition of the small GTPase Rab resulted in 
altered osteoclast morphology characterized by dome shaped cells with large intracellular 
vacuoles (35). They reported that the antiresorptive properties of the Rab inhibitor were likely 
due to disruption of Rab-dependent intracellular membrane trafficking in osteoclasts.  
   ZOL significantly reduced bone resorption in this model of bone-invasive OSCC; however 
ZOL failed to completely inhibit osteoclastic bone resorption. Tumor bearing mice continued to 
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lose preexisting bone in the face of ZOL therapy, albeit at a reduced level. A recent in vitro study 
revealed that a human OSCC cell line was capable of reducing osteoclast apoptosis through 
down regulation of the pro-apoptotic factor BIM (36). Osteoclasts in the SCCF2Luc tumor-bone 
microenvironment may have been partially protected from the proapoptotic effects of ZOL by 
factors produced by FOSCC cells.  
   Hypercalcemia associated with elevated circulating PTHrP has been occasionally reported in 
people with oral squamous cell carcinoma; but is rarely observed in cats with FOSCC. Plasma 
PTHrP levels were mildly elevated in mice bearing SCCF2Luc xenografts (attributed to 
xenograft production of PTHrP), but there was no associated increase in total calcium. Although 
there was no evidence of a humoral role of PTHrP in this model, PTHrP may have functioned in 
a paracrine manner to stimulate osteoclastic bone resorption. 
   Various adverse effects have been reported for NBP therapy; although osteonecrosis of the jaw 
(ONJ) has warranted the most concern. ONJ is characterized by exposed, necrotic jaw bone and 
has been observed in patients treated with NBPs (37). The incidence of ONJ among human 
patients receiving intravenous NBP therapy is 5 - 10% (38). In this study, ZOL was well 
tolerated in both the tumor-bearing and non-tumor bearing mice and there was no evidence of 
ONJ, however longer studies are required to fully characterize the risk of developing ONJ. 
  This preclinical model of OSCC recapitulates the bone invasive phenotype characteristic of the 
disease in both humans and cats, and will be useful to future preclinical studies of bone invasive 
OSCC regardless of species. ZOL reduced FOSCC-induced osteolysis and bioluminescence, but 
invasive behavior was unchanged. The results of this experiment suggest that ZOL monotherapy 
would be of limited efficacy in the management of FOSCC, but may be valuable as adjunct 
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Legends for illustrations: 
Figure 1. ZOL treatment reduced SCCF2Luc xenograft growth. 
A, Six representative mice from each group are shown, illustrating the bioluminescent image 
following 28 days of treatment. B, Mice were imaged at day 1,7,21 and 28 days of treatment. 
The fold change in radiance was determined for each mouse by dividing the ROI radiance values 
on days 7, 21 and 28 by the initial ROI values from day 1. On day 28, the fold change radiance 
was reduced 43% in ZOL-treated mice compared to vehicle treated mice (*P=0.004).  
Figure 2. ZOL reduced SCCF2Luc xenograft area. 
Histomorphometric evaluation of histologic tumor sections revealed that ZOL-treatment reduced 
adjusted tumor area (total area minus areas of necrosis) by 14% (*P=0.0375).  
Figure 3. ZOL inhibited SCCF2Luc xenograft-induced osteolysis. 
A, Faxitron radiography (post mortem, mandibles removed) of 3 representative mice from each 
treatment group (xenograft margins = white arrows, osteolysis = red arrows, new bone formation 
= blue asterisks). Zoledronic acid treatment was associated with reduced osteolysis and increased 
periosteal new bone formation compared to vehicle treated mice. B, Images representing 3 
dimensional renderings of microcomputed tomography (μCT) data. Normal premaxillary bone 
(white arrow) and maxillary bone (blue arrow) are indicated on the Sham + Vehicle mouse. 
SCCF2Luc xenografts in vehicle treated mice were associated with marked loss of lateral pre-
maxillary and maxillary bone revealing the root of the maxillary incisor (red arrows). Zoledronic 
acid treatment resulted in reduced osteolysis of maxillary and premaxillary bone (minimal 
exposure of incisor root, red circle) and increased periosteal new bone formation. C, A 2mm 
thick region of interest (ROI) incorporating pre-maxillary and maxillary bone was selected using 
µCT and image analysis software (red band), allowing bone surface area and bone volume to be 
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calculated and compared between treatment groups. 
Figure 4. ZOL prevented loss of bone surface area and bone volume in SCCF2Luc 
xenograft bearing mice. 
SCCF2Luc xenograft growth resulted in a significant reduction in bone surface area (13.9%, 
*P<0.0001) and bone volume (18.9%, *P<0.0001) compared to non-tumor bearing mice. ZOL 
prevented loss of bone surface area and bone volume (no statistically significant difference 
between ZOL-only mice and ZOL-SCCF2Luc tumor-bearing mice).  
Figure 5.  ZOL reduced histologic evidence of SCCF2Luc-associated osteolysis.  
A, SCCF2Luc xenografts were associated with marked osteolysis of the adjacent premaxillary 
and maxillary bone (white asterisks) along the infiltrating front of the tumor (black arrows, bar = 
500μm). B, Higher magnification from Panel A (box), illustrating islands of squamous cell 
carcinoma cells (arrows) infiltrating the remaining bone (white asterisk, bar = 100μm). C, 
Treatment with zoledronic acid resulted in reduced resorption of premaxillary and maxillary 
bone (black asterisks, Bar = 500μm). Despite reduced bone resorption, higher magnification (D) 
reveals islands of squamous cell carcinoma cells infiltrating the bone and the periodontal 
ligament (black arrows, bar = 100μm). Frequency of SCCF2Luc xenograft invasion into the skull 
was similar in both groups of mice. There was no difference in the incidence of xenograft 
invasion between vehicle-treated and ZOL-treated mice.   
Figure 6. ZOL-mediated sparing of bone loss was characterized by reduced loss of 
preexisting bone balanced by increased new bone formation. 
SCCF2Luc xenografts were associated with a 47.7% reduction in total bone area (preexisiting 
bone and new bone combined) compared to the non-tumor bearing side (*P=0.0002), whereas 
ZOL treatment prevented loss of total bone area. Xenograft growth was associated with a 64.1% 
16 
 
reduction in preexisting bone (*P=0.0003) in vehicle treated mice, however loss of preexisiting 
bone was reduced to 33.3% in ZOL-treated mice (*P=0.0001). ZOL treated mice retained 2-fold 
more preexisiting bone compared to vehicle treated mice (*P=0.005). The preservation of total 
bone in ZOL-treated mice is attributed to reduced loss of preexisting bone and increased new 
bone formation.  
Figure 7. ZOL reduced the number of bone-resorbing osteoclasts at the tumor-bone 
interface. 
Histomorphometric evaluation of TRAP-stained slides revealed no difference in the percentage 
of eroded bone between ZOL and vehicle treated mice, however the percentage of bone in direct 
contact with activated osteoclasts to total bone surface was reduced by 33.4% (*P=0.017). ZOL 
reduced the number of osteoclasts per millimeter by 51.8% (*P=0.0001). The average osteoclast 
length was increased in the ZOL-treated mice by 39.1% (*P=0.0001).  
Figure 8. Osteoclasts in ZOL-treated mice were characterized by vacuolar degeneration. 
Osteoclasts were multinucleated (small black arrows), and in ZOL-treated mice were 
characterized by vacuolar degeneration (large black arrows). Islands of FOSCC are indicated by 
‘T’.  
Figure 9. ZOL failed to reduce plasma PTHrP in mice bearing SCCF2Luc xenografts.  
Plasma PTHrP was elevated in tumor bearing mice (2.42 pM) compared to control mice 
(0.65pM, *P=0.037); however ZOL treatment did not significantly reduce plasma PTHrP values. 









































Figure 4. ZOL prevented loss of bone surface area and bone volume in SCCF2Luc 

























Figure 6. ZOL-mediated sparing of bone loss was characterized by reduced loss of 






































Figure 9. ZOL failed to reduce plasma PTHrP in mice bearing SCCF2Luc xenografts.  
 
